C-SCADE8

A cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk

Stadium: klaar
Middel: BI 10773 (empagliflozine)
Populatie: Diabetes Mellitus
Fase: fase III
First Patient In: 1 januari 2012
Last Patient In: 30 maart 2018
Last Patient Last Visit: -

Studiedirecteur

drs. P.R. Nierop

Cardioloog